S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Aerie Pharmaceuticals Stock Forecast, Price & News

+0.86 (+11.47%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
641,192 shs
Average Volume
788,696 shs
Market Capitalization
$406.49 million
P/E Ratio
Dividend Yield
Price Target

Aerie Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.75 Rating Score
148.5% Upside
$20.78 Price Target
Short Interest
8.11% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.66mentions of Aerie Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.21) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.92 out of 5 stars

Medical Sector

649th out of 1,429 stocks

Biological Products, Except Diagnostic Industry

105th out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Aerie Pharmaceuticals logo

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

AERI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-74.81 million
Pretax Margin


Sales & Book Value

Annual Sales
$194.13 million
Book Value
($0.37) per share


Free Float
Market Cap
$406.49 million

Aerie Pharmaceuticals Frequently Asked Questions

Should I buy or sell Aerie Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals
or view top-rated stocks.

What is Aerie Pharmaceuticals' stock price forecast for 2022?

4 analysts have issued twelve-month price targets for Aerie Pharmaceuticals' shares. Their AERI stock forecasts range from $13.00 to $29.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $20.78 in the next year. This suggests a possible upside of 148.5% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Aerie Pharmaceuticals' stock performed in 2022?

Aerie Pharmaceuticals' stock was trading at $7.02 at the start of the year. Since then, AERI shares have increased by 19.1% and is now trading at $8.36.
View the best growth stocks for 2022 here

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Aerie Pharmaceuticals

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.01. The business earned $29.84 million during the quarter, compared to analysts' expectations of $30.19 million. During the same quarter in the previous year, the company posted ($0.72) EPS.
View Aerie Pharmaceuticals' earnings history

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Mr. Raj Kannan, CEO, Principal Financial Officer & Director (Age 58, Pay $753.49k)
  • Dr. Casey C. Kopczynski Ph.D., Co-Founder, Chief Innovation Officer & Head of Research and External Innovation (Age 61, Pay $685.06k)
  • Mr. John W. LaRocca Esq., Gen. Counsel & Sec. (Age 57, Pay $676.62k)
  • Mr. Peter F. Lang, Chief Financial Officer (Age 50)
  • Dr. Michelle Senchyna Ph.D., Head of Clinical Devel. & Operations
  • Mr. Jeffrey M. Calabrese CPA, VP of Fin. & Principal Accounting Officer (Age 55)
  • Ms. Carolyn McAuliffe, Sr. Director of Communications
  • Ms. Wanda Francies, Head of HR
  • Mr. Marvin J. Garrett, Head of Regulatory Affairs & Quality Assurance (Age 71)
  • Mr. Craig R. Skenes, Head of Bus. Devel.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $8.36.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $406.49 million and generates $194.13 million in revenue each year. The company earns $-74.81 million in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

Aerie Pharmaceuticals employs 376 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for Aerie Pharmaceuticals is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at [email protected], or via fax at 949-526-8787.

This page (NASDAQ:AERI) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.